AGIOS PHARMACEUTICALS INC (AGIO) Stock Price, Quote, News and Overview
NASDAQ:AGIO - Nasdaq - US00847X1046 - Common Stock - Currency: USD
AGIO Quote, Performance and Key Statistics
35.22
+1.47 (+4.36%)
The current stock price of AGIO is 35.22 USD. In the past month the price decreased by -0.45%. In the past year, price increased by 6.76%.
AGIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AGIO
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 383 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The firm is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Company Info
AGIOS PHARMACEUTICALS INC
88 Sidney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Jacqualyn A. Fouse
Employees: 385
Company Website: https://www.agios.com/
Investor Relations: https://investor.agios.com
Phone: 16176498600
AGIOS PHARMACEUTICALS INC / AGIO FAQ
What is the stock price of AGIOS PHARMACEUTICALS INC today?
The current stock price of AGIO is 35.22 USD. The price increased by 4.36% in the last trading session.
What is the ticker symbol for AGIOS PHARMACEUTICALS INC stock?
The exchange symbol of AGIOS PHARMACEUTICALS INC is AGIO and it is listed on the Nasdaq exchange.
On which exchange is AGIO stock listed?
AGIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AGIOS PHARMACEUTICALS INC stock?
15 analysts have analysed AGIO and the average price target is 57.8 USD. This implies a price increase of 64.11% is expected in the next year compared to the current price of 35.22. Check the AGIOS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AGIOS PHARMACEUTICALS INC worth?
AGIOS PHARMACEUTICALS INC (AGIO) has a market capitalization of 2.01B USD. This makes AGIO a Mid Cap stock.
How many employees does AGIOS PHARMACEUTICALS INC have?
AGIOS PHARMACEUTICALS INC (AGIO) currently has 385 employees.
What are the support and resistance levels for AGIOS PHARMACEUTICALS INC (AGIO) stock?
AGIOS PHARMACEUTICALS INC (AGIO) has a support level at 33.84 and a resistance level at 35.23. Check the full technical report for a detailed analysis of AGIO support and resistance levels.
Is AGIOS PHARMACEUTICALS INC (AGIO) expected to grow?
The Revenue of AGIOS PHARMACEUTICALS INC (AGIO) is expected to grow by 128.49% in the next year. Check the estimates tab for more information on the AGIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AGIOS PHARMACEUTICALS INC (AGIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AGIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AGIO, evaluating the profitability, health, valuation and growth aspects
- AGIOS PHARMACEUTICALS INC (AGIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AGIOS PHARMACEUTICALS INC (AGIO) Sales and EPS estimates to see what analysts future expectations are.
- AGIOS PHARMACEUTICALS INC (AGIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AGIOS PHARMACEUTICALS INC (AGIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- AGIOS PHARMACEUTICALS INC (AGIO) Stock Chart to make your own analysis
- AGIOS PHARMACEUTICALS INC (AGIO) Latest news and press-releases to stay up to date.
Does AGIOS PHARMACEUTICALS INC (AGIO) stock pay dividends?
AGIO does not pay a dividend.
When does AGIOS PHARMACEUTICALS INC (AGIO) report earnings?
AGIOS PHARMACEUTICALS INC (AGIO) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of AGIOS PHARMACEUTICALS INC (AGIO)?
AGIOS PHARMACEUTICALS INC (AGIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7).
What is the Short Interest ratio of AGIOS PHARMACEUTICALS INC (AGIO) stock?
The outstanding short interest for AGIOS PHARMACEUTICALS INC (AGIO) is 9.15% of its float. Check the ownership tab for more information on the AGIO short interest.
AGIO Technical Analysis
AGIO Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AGIO. No worries on liquidiy or solvency for AGIO as it has an excellent financial health rating, but there are worries on the profitability.
AGIO Financial Highlights
Over the last trailing twelve months AGIO reported a non-GAAP Earnings per Share(EPS) of -7. The EPS decreased by -10.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1845.92% | ||
| ROA | 40.51% | ||
| ROE | 43.72% | ||
| Debt/Equity | 0 |
AGIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to AGIO. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -7.2% and a revenue growth 128.49% for AGIO